Faculty of Pharmacy, University of Khartoum, Khartoum, Sudan.
Faculty of Medicine, Alneelain University, Khartoum, Sudan.
Biomed Res Int. 2020 May 11;2020:2683286. doi: 10.1155/2020/2683286. eCollection 2020.
A new endemic disease has spread across Wuhan City, China, in December 2019. Within few weeks, the World Health Organization (WHO) announced a novel coronavirus designated as coronavirus disease 2019 (COVID-19). In late January 2020, WHO declared the outbreak of a "public-health emergency of international concern" due to the rapid and increasing spread of the disease worldwide. Currently, there is no vaccine or approved treatment for this emerging infection; thus, the objective of this study is to design a multiepitope peptide vaccine against COVID-19 using an immunoinformatics approach.
Several techniques facilitating the combination of the immunoinformatics approach and comparative genomic approach were used in order to determine the potential peptides for designing the T-cell epitope-based peptide vaccine using the envelope protein of 2019-nCoV as a target.
Extensive mutations, insertion, and deletion were discovered with comparative sequencing in the COVID-19 strain. Additionally, ten peptides binding to MHC class I and MHC class II were found to be promising candidates for vaccine design with adequate world population coverage of 88.5% and 99.99%, respectively.
The T-cell epitope-based peptide vaccine was designed for COVID-19 using the envelope protein as an immunogenic target. Nevertheless, the proposed vaccine rapidly needs to be validated clinically in order to ensure its safety and immunogenic profile to help stop this epidemic before it leads to devastating global outbreaks.
一种新的地方性疾病于 2019 年 12 月在中国武汉市蔓延。数周内，世界卫生组织（WHO）宣布一种新型冠状病毒，命名为 2019 年冠状病毒病（COVID-19）。2020 年 1 月下旬，由于该疾病在全球范围内迅速且不断蔓延，世界卫生组织宣布该疫情为“国际关注的突发公共卫生事件”。目前，尚无针对这种新发感染的疫苗或批准的治疗方法；因此，本研究旨在使用免疫信息学方法设计针对 COVID-19 的多表位肽疫苗。
使用了几种促进免疫信息学方法与比较基因组学方法相结合的技术，以便使用 2019-nCoV 包膜蛋白作为靶标，确定设计基于 T 细胞表位的肽疫苗的潜在肽。
通过比较测序发现 COVID-19 株有广泛的突变、插入和缺失。此外，发现有十个与 MHC Ⅰ类和 MHC Ⅱ类结合的肽有望成为疫苗设计的候选物，其对全球人口的覆盖率分别为 88.5%和 99.99%。
使用包膜蛋白作为免疫原性靶标，设计了针对 COVID-19 的基于 T 细胞表位的肽疫苗。然而，该疫苗需要迅速在临床上进行验证，以确保其安全性和免疫原性，从而帮助阻止该流行病在导致毁灭性的全球爆发之前。
